SYNTHESIS OF FLUOROARACHIDONIC ACID AND METHODS OF USE THEREOF

There are provided, inter alia, methods for diagnosis of the extent of neuroinflammation in a subject. The methods include administering an F-labeled arachidonic acid to a subject in need thereof, obtaining a positron emission tomography (PET) scan of the subject, and determine the extent of neuroinflammation from the PET scan. There are provided, inter alia, methods of synthesis of reagents useful for the production of an F-labeled arachidonic acid. 1. A method of diagnosis of the extent of neuroinflammation in a subject , said method comprising:{'sup': '18', 'administering an F-labeled arachidonic acid to a subject in need thereof;'}obtaining a positron emission tomography (PET) scan of said subject; anddetermining the extent of neuroinflammation of said subject from said PET scan.2. The method of claim 1 , wherein said F-labeled arachidonic acid is [20-F] arachidonic acid.3. The method of claim 1 , wherein said neuroinflammation is associated with Alzheimer's disease claim 1 , bipolar disorder claim 1 , schizophrenia claim 1 , Parkinson's disease claim 1 , HIV-1 associated dementia claim 1 , brain trauma claim 1 , epilepsy claim 1 , cancer or bacterial infections.4. The method of claim 2 , wherein said neuroinflammation is associated with Alzheimer's disease claim 2 , bipolar disorder claim 2 , schizophrenia claim 2 , Parkinson's disease claim 2 , HIV-1 associated dementia claim 2 , brain trauma claim 2 , epilepsy claim 2 , cancer or bacterial infections.5. A method for producing methyl 20-(p-toluenesulfonyloxy)-5 claim 2 ,8 claim 2 ,11 claim 2 ,14-eicosatetraenoate claim 2 , said method comprising reacting methyl 20-hydroxy-5 claim 2 ,8 claim 2 ,11 claim 2 ,14-eicosatetraenoate with tosyl chloride and triethylamine in dichloromethane.6. A method for producing methyl 20-fluoroarachidonate claim 2 , said method comprising reacting methyl 20-(p-toluenesulfonyloxy)-5 claim 2 ,8 claim 2 ,11 claim 2 ,14-eicosatetraenoate with tetra-n-butylammonium fluoride in ...

Method of stably radiolabeling antibodies with technetium and rhenium

99 m Tc-labeling of antibodies and antibody fragments, either unconjugated or conjugated to DTPA, is effected in the presence of molar excess of free or carrier-bound DTPA to substantially completely inhibit direct technetium binding to non-stable binding sites on the antibody. The resultant 99m Tc-labeled antibody has a stable label and is useful for, inter alia, tumor imaging by gamma scintigraphy and/or tumor therapy. Rhenium-labeling can be similarly effected.

Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group

Boronic acid adducts of technetium-99m and radioactive rhenium dioxime complexes, each of which include biochemically active groups, are useful as diagnostic and therapeutic agents, respectively.

Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof

One aspect of the invention relates to complexes of technetium (Tc) and rhenium (Re) with various heteroaromatic ligands, e.g., quinolinyl and isoquinolinyl ligands, and their use in fluoresence and radioimaging for a variety of clinical diagnostic applications, as well as radiopharmaceuticals for therapeutic applications. Another aspect of the invention relates to quinolinyl and isoquinolinyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium and rhenium complexes are also described. Another aspect of the invention relates to quinolinyl and isoquinolinyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.

Radiolabeled derivatives of potent chymase inhibitors

Methods of imaging tissue of a mammal which expresses chymase include administering to the mammal an effective amount of a radiolabeled chymase inhibitor. Radiopharmaceuticals that may be used in diagnostic imaging and therapeutic treatment of disease characterized by expression of chymase have the structure of Formula I:

Boronic acid adducts of rhenium dioxide and technetium-99m dioxime complexes containing a biologically active group, and diagnostic imaging and radiotherapy compositions thereof

3-chinuclidinil glicolati legantidi recettori ed emettenti raggi gamma, metodo di loro preparazione e metodi di visualizzazione e analisi mediante loro impiego.

3-chinuclidinil glicolati leganti di recettori ed elementi raggi gamma,metodo di loro preparazione e metodi di visualizzazione e analisi mediante loro impiego

Chinuclodinil benzilati leganti di recettori e emettenti raggi gamma,metodi di loro preparazione e metodi di visualizzazione ed analisi mediante loro utilizzazione

Metodi di visualizzazione edchinuclodinil benzilati leganti di analisi mediante loro recettori e emettenti raggi gamma, utilizzazione. metodi di loro preparazione e